Merus (MRUS) director Haddock returned to the company 30,881 Share Option (right to buy)

Insider transactions reported

Jason Haddock (director at Merus N.V., MRUS) reported that they returned to the company 30,881 Share Option (right to buy) on Dec 12, 2025.

Reporting person

Haddock Jason

Options and other derivatives

Holdings before and after

• Share Option (right to buy): 13,193 to 0 direct

Footnotes from the filing

1. 1. On September 29, 2025, Merus N.V. (the Issuer ) entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the Transaction Agreement ) with Genmab A/S ( Genmab ) and its wholly owned subsidiary, Genmab Holding II B.V. (the Purchaser ). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the Shares ), of the Issuer (the Offer ), and, on December 12, 2025 (the Acceptance Time ), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the Offer Consideration ), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.
2. 2. This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

Transaction codes in this filing

Sale back to the company:

Code D marks a disposition back to the company under an exempt plan, as opposed to a sale in the market.

FAQ